Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 235

1.

Preclinical efficacy of endoglin-targeting antibody-drug conjugates for the treatment of Ewing sarcoma.

Puerto-Camacho P, Amaral AT, Lamhamedi-Cherradi SE, Menegaz BA, Castillo-Ecija H, Ordóñez JL, Dominguez-Hormaetxe S, Jordan-Perez C, Diaz-Martin J, Romero-Pérez L, Lopez-Alvarez M, Civantos-Jubera G, Robles-Frias MJ, Biscuola M, Ferrer C, Mora J, Cuglievan B, Schadler KL, Seifert O, Kontermann RE, Pfizenmaier K, Simon L, Fabre M, Carcaboso AM, Ludwig JA, de Álava E.

Clin Cancer Res. 2018 Nov 12. pii: clincanres.0936.2018. doi: 10.1158/1078-0432.CCR-18-0936. [Epub ahead of print]

PMID:
30420447
2.

Monovalent TNF receptor 1-selective antibody with improved affinity and neutralizing activity.

Richter F, Zettlitz KA, Seifert O, Herrmann A, Scheurich P, Pfizenmaier K, Kontermann RE.

MAbs. 2018 Sep 25:1-12. doi: 10.1080/19420862.2018.1524664. [Epub ahead of print]

PMID:
30252601
3.

Duokines: a novel class of dual-acting co-stimulatory molecules acting in cis or trans.

Fellermeier-Kopf S, Gieseke F, Sahin U, Müller D, Pfizenmaier K, Kontermann RE.

Oncoimmunology. 2018 Aug 1;7(9):e1471442. doi: 10.1080/2162402X.2018.1471442. eCollection 2018.

4.

Anti-TNFR1 targeting in humanized mice ameliorates disease in a model of multiple sclerosis.

Williams SK, Fairless R, Maier O, Liermann PC, Pichi K, Fischer R, Eisel ULM, Kontermann R, Herrmann A, Weksler B, Romero N, Couraud PO, Pfizenmaier K, Diem R.

Sci Rep. 2018 Sep 11;8(1):13628. doi: 10.1038/s41598-018-31957-7.

5.

IgG-single-chain TRAIL fusion proteins for tumour therapy.

Siegemund M, Schneider F, Hutt M, Seifert O, Müller I, Kulms D, Pfizenmaier K, Kontermann RE.

Sci Rep. 2018 May 17;8(1):7808. doi: 10.1038/s41598-018-24450-8.

6.

Targeting scFv-Fc-scTRAIL fusion proteins to tumor cells.

Hutt M, Fellermeier-Kopf S, Seifert O, Schmitt LC, Pfizenmaier K, Kontermann RE.

Oncotarget. 2018 Jan 31;9(13):11322-11335. doi: 10.18632/oncotarget.24379. eCollection 2018 Feb 16.

7.

Selective Activation of Tumor Necrosis Factor Receptor II Induces Antiinflammatory Responses and Alleviates Experimental Arthritis.

Fischer R, Proske M, Duffey M, Stangl H, Martinez GF, Peters N, Kraske A, Straub RH, Bethea JR, Kontermann RE, Pfizenmaier K.

Arthritis Rheumatol. 2018 May;70(5):722-735. doi: 10.1002/art.40413. Epub 2018 Mar 11.

PMID:
29342501
8.

Superior Properties of Fc-comprising scTRAIL Fusion Proteins.

Hutt M, Marquardt L, Seifert O, Siegemund M, Müller I, Kulms D, Pfizenmaier K, Kontermann RE.

Mol Cancer Ther. 2017 Dec;16(12):2792-2802. doi: 10.1158/1535-7163.MCT-17-0551. Epub 2017 Sep 13.

PMID:
28904131
9.

Novel strategies to mimic transmembrane tumor necrosis factor-dependent activation of tumor necrosis factor receptor 2.

Fischer R, Marsal J, Guttà C, Eisler SA, Peters N, Bethea JR, Pfizenmaier K, Kontermann RE.

Sci Rep. 2017 Jul 26;7(1):6607. doi: 10.1038/s41598-017-06993-4.

10.

Antitumor Activity of a Mesenchymal Stem Cell Line Stably Secreting a Tumor-Targeted TNF-Related Apoptosis-Inducing Ligand Fusion Protein.

Marini I, Siegemund M, Hutt M, Kontermann RE, Pfizenmaier K.

Front Immunol. 2017 May 11;8:536. doi: 10.3389/fimmu.2017.00536. eCollection 2017.

11.

Essential protective role of tumor necrosis factor receptor 2 in neurodegeneration.

Dong Y, Fischer R, Naudé PJ, Maier O, Nyakas C, Duffey M, Van der Zee EA, Dekens D, Douwenga W, Herrmann A, Guenzi E, Kontermann RE, Pfizenmaier K, Eisel UL.

Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):12304-12309. Epub 2016 Oct 10.

12.

Selective Blocking of TNF Receptor 1 Attenuates Peritoneal Dialysis Fluid Induced Inflammation of the Peritoneum in Mice.

Kälble F, Damaske J, Heide D, Arnold I, Richter F, Maier O, Eisel U, Scheurich P, Pfizenmaier K, Zeier M, Schwenger V, Ranzinger J.

PLoS One. 2016 Oct 18;11(10):e0163314. doi: 10.1371/journal.pone.0163314. eCollection 2016.

13.

An optimized antibody-single-chain TRAIL fusion protein for cancer therapy.

Siegemund M, Seifert O, Zarani M, Džinić T, De Leo V, Göttsch D, Münkel S, Hutt M, Pfizenmaier K, Kontermann RE.

MAbs. 2016 Jul;8(5):879-91. doi: 10.1080/19420862.2016.1172163. Epub 2016 Apr 11.

14.

Protein kinase D promotes plasticity-induced F-actin stabilization in dendritic spines and regulates memory formation.

Bencsik N, Szíber Z, Liliom H, Tárnok K, Borbély S, Gulyás M, Rátkai A, Szűcs A, Hazai-Novák D, Ellwanger K, Rácz B, Pfizenmaier K, Hausser A, Schlett K.

J Cell Biol. 2015 Aug 31;210(5):771-83. doi: 10.1083/jcb.201501114. Epub 2015 Aug 24.

15.

Tailoring the stealth properties of biocompatible polysaccharide nanocontainers.

Kang B, Okwieka P, Schöttler S, Seifert O, Kontermann RE, Pfizenmaier K, Musyanovych A, Meyer R, Diken M, Sahin U, Mailänder V, Wurm FR, Landfester K.

Biomaterials. 2015 May;49:125-34. doi: 10.1016/j.biomaterials.2015.01.042. Epub 2015 Feb 16.

PMID:
25725561
16.

A new tool for the quantitative analysis of dendritic filopodial motility.

Tárnok K, Gulyás M, Bencsik N, Ferenc K, Pfizenmaier K, Hausser A, Schlett K.

Cytometry A. 2015 Jan;87(1):89-96. doi: 10.1002/cyto.a.22569. Epub 2014 Sep 24.

17.

EGFR-targeted TRAIL and a Smac mimetic synergize to overcome apoptosis resistance in KRAS mutant colorectal cancer cells.

Möller Y, Siegemund M, Beyes S, Herr R, Lecis D, Delia D, Kontermann R, Brummer T, Pfizenmaier K, Olayioye MA.

PLoS One. 2014 Sep 8;9(9):e107165. doi: 10.1371/journal.pone.0107165. eCollection 2014.

18.

Immuno-LipoTRAIL: Targeted delivery of TRAIL-functionalized liposomal nanoparticles.

Seifert O, Pollak N, Nusser A, Steiniger F, Rüger R, Pfizenmaier K, Kontermann RE.

Bioconjug Chem. 2014 May 21;25(5):879-87. doi: 10.1021/bc400517j. Epub 2014 May 7.

PMID:
24766622
19.

Antibody-mediated inhibition of TNFR1 attenuates disease in a mouse model of multiple sclerosis.

Williams SK, Maier O, Fischer R, Fairless R, Hochmeister S, Stojic A, Pick L, Haar D, Musiol S, Storch MK, Pfizenmaier K, Diem R.

PLoS One. 2014 Feb 28;9(2):e90117. doi: 10.1371/journal.pone.0090117. eCollection 2014.

20.

A mouse bone marrow stromal cell line with skeletal stem cell characteristics to study osteogenesis in vitro and in vivo.

Raeth S, Sacchetti B, Siegel G, Mau-Holzmann UA, Hansmann J, Vacun G, Hauk TG, Pfizenmaier K, Hausser A.

Stem Cells Dev. 2014 May 15;23(10):1097-108. doi: 10.1089/scd.2013.0367. Epub 2014 Feb 18.

PMID:
24405418
21.

Protein kinase D2 induces invasion of pancreatic cancer cells by regulating matrix metalloproteinases.

Wille C, Köhler C, Armacki M, Jamali A, Gössele U, Pfizenmaier K, Seufferlein T, Eiseler T.

Mol Biol Cell. 2014 Feb;25(3):324-36. doi: 10.1091/mbc.E13-06-0334. Epub 2013 Dec 11.

22.

Astrocyte-specific activation of TNFR2 promotes oligodendrocyte maturation by secretion of leukemia inhibitory factor.

Fischer R, Wajant H, Kontermann R, Pfizenmaier K, Maier O.

Glia. 2014 Feb;62(2):272-83. doi: 10.1002/glia.22605. Epub 2013 Dec 6.

PMID:
24310780
23.

Tetravalent antibody-scTRAIL fusion proteins with improved properties.

Seifert O, Plappert A, Fellermeier S, Siegemund M, Pfizenmaier K, Kontermann RE.

Mol Cancer Ther. 2014 Jan;13(1):101-11. doi: 10.1158/1535-7163.MCT-13-0396. Epub 2013 Oct 3.

24.

TNF receptor 2 protects oligodendrocyte progenitor cells against oxidative stress.

Maier O, Fischer R, Agresti C, Pfizenmaier K.

Biochem Biophys Res Commun. 2013 Oct 18;440(2):336-41. doi: 10.1016/j.bbrc.2013.09.083. Epub 2013 Sep 25.

PMID:
24076392
25.

An anti-TNFR1 scFv-HSA fusion protein as selective antagonist of TNF action.

Berger V, Richter F, Zettlitz K, Unverdorben F, Scheurich P, Herrmann A, Pfizenmaier K, Kontermann RE.

Protein Eng Des Sel. 2013 Oct;26(10):581-7. doi: 10.1093/protein/gzt044. Epub 2013 Sep 4.

PMID:
24006371
26.

Antagonistic TNF receptor one-specific antibody (ATROSAB): receptor binding and in vitro bioactivity.

Richter F, Liebig T, Guenzi E, Herrmann A, Scheurich P, Pfizenmaier K, Kontermann RE.

PLoS One. 2013 Aug 19;8(8):e72156. doi: 10.1371/journal.pone.0072156. eCollection 2013.

27.

Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma.

Kakarla S, Chow KK, Mata M, Shaffer DR, Song XT, Wu MF, Liu H, Wang LL, Rowley DR, Pfizenmaier K, Gottschalk S.

Mol Ther. 2013 Aug;21(8):1611-20. doi: 10.1038/mt.2013.110. Epub 2013 Jun 4.

28.

Increased apoptosis induction in hepatocellular carcinoma by a novel tumor-targeted TRAIL fusion protein combined with bortezomib.

Wahl K, Siegemund M, Lehner F, Vondran F, Nüssler A, Länger F, Krech T, Kontermann R, Manns MP, Schulze-Osthoff K, Pfizenmaier K, Bantel H.

Hepatology. 2013 Feb;57(2):625-36. doi: 10.1002/hep.26082. Epub 2013 Jan 8.

PMID:
22991197
29.

Role of caspases in cytokine-induced barrier breakdown in human brain endothelial cells.

Lopez-Ramirez MA, Fischer R, Torres-Badillo CC, Davies HA, Logan K, Pfizenmaier K, Male DK, Sharrack B, Romero IA.

J Immunol. 2012 Sep 15;189(6):3130-9. doi: 10.4049/jimmunol.1103460. Epub 2012 Aug 15.

30.

Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells.

Franz-Wachtel M, Eisler SA, Krug K, Wahl S, Carpy A, Nordheim A, Pfizenmaier K, Hausser A, Macek B.

Mol Cell Proteomics. 2012 May;11(5):160-70. doi: 10.1074/mcp.M111.016014. Epub 2012 Apr 10.

31.

Superior antitumoral activity of dimerized targeted single-chain TRAIL fusion proteins under retention of tumor selectivity.

Siegemund M, Pollak N, Seifert O, Wahl K, Hanak K, Vogel A, Nussler AK, Göttsch D, Münkel S, Bantel H, Kontermann RE, Pfizenmaier K.

Cell Death Dis. 2012 Apr 12;3:e295. doi: 10.1038/cddis.2012.29.

32.

A TNF receptor 2 selective agonist rescues human neurons from oxidative stress-induced cell death.

Fischer R, Maier O, Siegemund M, Wajant H, Scheurich P, Pfizenmaier K.

PLoS One. 2011;6(11):e27621. doi: 10.1371/journal.pone.0027621. Epub 2011 Nov 14.

33.

G-PKDrep-live, a genetically encoded FRET reporter to measure PKD activity at the trans-Golgi-network.

Eisler SA, Fuchs YF, Pfizenmaier K, Hausser A.

Biotechnol J. 2012 Jan;7(1):148-54. doi: 10.1002/biot.201100273. Epub 2011 Nov 7.

PMID:
21898831
34.

Protein kinase D controls voluntary-running-induced skeletal muscle remodelling.

Ellwanger K, Kienzle C, Lutz S, Jin ZG, Wiekowski MT, Pfizenmaier K, Hausser A.

Biochem J. 2011 Dec 15;440(3):327-4. doi: 10.1042/BJ20101980.

35.

Therapeutic targeting of CD95 and the TRAIL death receptors.

Gerspach J, Pfizenmaier K, Wajant H.

Recent Pat Anticancer Drug Discov. 2011 Sep;6(3):294-310. doi: 10.2174/157489211796957739. Review.

PMID:
21762072
36.

Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteins.

Schneider B, Münkel S, Krippner-Heidenreich A, Grunwald I, Wels WS, Wajant H, Pfizenmaier K, Gerspach J.

Cell Death Dis. 2010 Aug 26;1:e68. doi: 10.1038/cddis.2010.45.

37.

Engineering death receptor ligands for cancer therapy.

Wajant H, Gerspach J, Pfizenmaier K.

Cancer Lett. 2013 May 28;332(2):163-74. doi: 10.1016/j.canlet.2010.12.019. Epub 2011 Jan 14. Review.

PMID:
21236560
38.

Genetic engineering of death ligands for improvement of therapeutic activity.

Gerspach J, Schneider B, Müller N, Otz T, Wajant H, Pfizenmaier K.

Adv Exp Med Biol. 2011;691:507-19. doi: 10.1007/978-1-4419-6612-4_53. No abstract available.

PMID:
21153356
39.

Workshop Summary: Introduction to Rational Design of New Means for Therapeutic Modulation of Function of the TNF Family.

Pfizenmaier K, Szymkowski DE.

Adv Exp Med Biol. 2011;691:487-91. doi: 10.1007/978-1-4419-6612-4_50. No abstract available.

PMID:
21153353
40.

Neuroprotective and neurodegenerative effects of the chronic expression of tumor necrosis factor α in the nigrostriatal dopaminergic circuit of adult mice.

Chertoff M, Di Paolo N, Schoeneberg A, Depino A, Ferrari C, Wurst W, Pfizenmaier K, Eisel U, Pitossi F.

Exp Neurol. 2011 Feb;227(2):237-51. doi: 10.1016/j.expneurol.2010.11.010. Epub 2010 Nov 17.

PMID:
21093436
41.

ATROSAB, a humanized antagonistic anti-tumor necrosis factor receptor one-specific antibody.

Zettlitz KA, Lorenz V, Landauer K, Münkel S, Herrmann A, Scheurich P, Pfizenmaier K, Kontermann R.

MAbs. 2010 Nov-Dec;2(6):639-47. Epub 2010 Nov 1.

42.

Ligand-induced internalization of TNF receptor 2 mediated by a di-leucin motif is dispensable for activation of the NFκB pathway.

Fischer R, Maier O, Naumer M, Krippner-Heidenreich A, Scheurich P, Pfizenmaier K.

Cell Signal. 2011 Jan;23(1):161-70. doi: 10.1016/j.cellsig.2010.08.016. Epub 2010 Aug 31.

PMID:
20807567
43.

Superior serum half life of albumin tagged TNF ligands.

Müller N, Schneider B, Pfizenmaier K, Wajant H.

Biochem Biophys Res Commun. 2010 Jun 11;396(4):793-9. doi: 10.1016/j.bbrc.2010.04.134. Epub 2010 May 4.

PMID:
20447380
44.

Protein kinase D controls actin polymerization and cell motility through phosphorylation of cortactin.

Eiseler T, Hausser A, De Kimpe L, Van Lint J, Pfizenmaier K.

J Biol Chem. 2010 Jun 11;285(24):18672-83. doi: 10.1074/jbc.M109.093880. Epub 2010 Apr 2.

45.

Antiestrogens induce transforming growth factor beta-mediated immunosuppression in breast cancer.

Joffroy CM, Buck MB, Stope MB, Popp SL, Pfizenmaier K, Knabbe C.

Cancer Res. 2010 Feb 15;70(4):1314-22. doi: 10.1158/0008-5472.CAN-09-3292. Epub 2010 Feb 9.

46.

Evaluation of a combinatorial cell engineering approach to overcome apoptotic effects in XBP-1(s) expressing cells.

Becker E, Florin L, Pfizenmaier K, Kaufmann H.

J Biotechnol. 2010 Apr 15;146(4):198-206. doi: 10.1016/j.jbiotec.2009.11.018. Epub 2009 Dec 1.

PMID:
19958799
47.

Trimer stabilization, oligomerization, and antibody-mediated cell surface immobilization improve the activity of soluble trimers of CD27L, CD40L, 41BBL, and glucocorticoid-induced TNF receptor ligand.

Wyzgol A, Müller N, Fick A, Munkel S, Grigoleit GU, Pfizenmaier K, Wajant H.

J Immunol. 2009 Aug 1;183(3):1851-61. doi: 10.4049/jimmunol.0802597. Epub 2009 Jul 13.

48.

Protein kinase D regulates cell migration by direct phosphorylation of the cofilin phosphatase slingshot 1 like.

Peterburs P, Heering J, Link G, Pfizenmaier K, Olayioye MA, Hausser A.

Cancer Res. 2009 Jul 15;69(14):5634-8. doi: 10.1158/0008-5472.CAN-09-0718. Epub 2009 Jun 30.

49.

Improving TNF as a cancer therapeutic: tailor-made TNF fusion proteins with conserved antitumor activity and reduced systemic side effects.

Gerspach J, Pfizenmaier K, Wajant H.

Biofactors. 2009 Jul-Aug;35(4):364-72. doi: 10.1002/biof.50. Review.

PMID:
19484741
50.

A Golgi PKD activity reporter reveals a crucial role of PKD in nocodazole-induced Golgi dispersal.

Fuchs YF, Eisler SA, Link G, Schlicker O, Bunt G, Pfizenmaier K, Hausser A.

Traffic. 2009 Jul;10(7):858-67. doi: 10.1111/j.1600-0854.2009.00918.x. Epub 2009 Apr 25.

Supplemental Content

Loading ...
Support Center